Gregory Curhan
About Gregory Curhan
Gregory S. Curhan, age 62, serves as Serina Therapeutics’ Chief Financial Officer in a non‑employee consultant role effective August 16, 2024; he is a Partner at FLG Partners (since January 2020) and holds a B.A. in Economics from Dartmouth College . His compensation for CFO services is paid at $650 per hour to FLG Partners under a consultant agreement; he also received an option grant for 250,000 shares that vests monthly over 48 months, with vesting acceleration upon a change in control or completion of a $60 million equity transaction . Company “Pay vs. Performance” disclosure cites TSR-based valuation of a fixed $100 investment at $30 in 2023 and $44 in 2024, with net income of $5,269k in 2023 and a loss of $(11,141)k in 2024; the Compensation Committee did not use this disclosure for pay decisions .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| Angion Biomedica Corp. | Chief Financial Officer | Jun 2020 – Jun 2023 | Public biotech CFO experience |
| Providence Medical Technology | Chief Financial Officer & SVP Corporate Development | Dec 2016 – Jan 2020 | Finance leadership; corporate development |
| Brighton Jones | Business Development Officer | Dec 2012 – Dec 2016 | Wealth management business development |
External Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| FLG Partners | Partner | Jan 2020 – present | CFO services firm; Serina compensates FLG $650/hour for Curhan’s work |
| Curevo Vaccines | Chief Financial Officer | 2020 – present | Venture‑backed biotech (infectious disease immunology) CFO |
Fixed Compensation
| Year | Base Salary ($) | Target Bonus (%) | Actual Bonus ($) | Option Awards Grant-Date Fair Value ($) | All Other Compensation ($) | Total ($) |
|---|---|---|---|---|---|---|
| 2024 | — | — | — | 1,447,750 | 252,663 (includes $25,000 retainer deposit to FLG Partners) | 1,700,413 |
- Consultant compensation terms: $650/hour paid to FLG Partners for Curhan’s services as CFO .
Performance Compensation
- Serina supplements fixed pay with discretionary bonuses and does not adopt quantified financial performance measures for incentive awards; a Clawback Policy applies to compensation granted, earned, or vested based on financial reporting measures in the event of certain restatements .
| Incentive Type | Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|---|
| Annual cash bonus (CFO) | Discretionary; no quantified metrics disclosed | N/A | N/A | N/A | — (2024) | N/A |
Equity Awards – Grant Details and Vesting
| Grant Date | Type | Shares | Strike ($) | Expiration | Vesting Schedule | Acceleration Triggers |
|---|---|---|---|---|---|---|
| 8/15/2024 | Stock options | 250,000 | 6.66 | 8/15/2034 | Monthly installments beginning 9/15/2024; fully vested on fourth anniversary of grant date, subject to continued service | Vesting accelerates upon change in control or completion of a $60 million equity transaction |
Equity Ownership & Alignment
| As-of Date | Holder | Shares Beneficially Owned | Percent of Outstanding | Composition / Notes |
|---|---|---|---|---|
| 9/17/2025 | Gregory Curhan | 78,120 | <1% | Consists of options exercisable within 60 days |
| As-of Date | Exercisable Options (#) | Unexercisable Options (#) |
|---|---|---|
| 12/31/2024 | 20,833 | 229,167 |
- Pledging/Hedging: No pledging disclosed for Curhan; beneficial ownership footnotes describe exercisable options only .
- Ownership guidelines: Not disclosed for executives; Company relies on multi‑year vesting to align interests .
Employment Terms
| Term | Details |
|---|---|
| Role & Effective Date | CFO in non‑employee consultant role, effective August 16, 2024 |
| Compensation Rate | $650 per hour paid to FLG Partners for Curhan’s services |
| Severance | No post‑employment severance or change‑in‑control payments; exception is accelerated option vesting upon change in control or completion of a $60 million equity transaction |
| Equity Acceleration | Options vesting accelerates upon change in control or $60 million equity financing |
| Non‑compete / Non‑solicit | Not disclosed for Curhan (consultant agreement summary) |
| Clawback | Company Clawback Policy applicable to compensation tied wholly or partly to financial reporting measures in the event of restatements |
| Related‑Party Transactions | None exceeding $120,000 involving Curhan since January 1, 2023 |
Performance & Track Record
- Public company CFO experience (Angion Biomedica) and multiple private/venture‑backed roles; current parallel responsibilities at FLG Partners and Curevo Vaccines .
- Company “Pay vs. Performance” table indicates TSR-based valuation of $100 investment at $30 (2023) and $44 (2024), and net income of $5,269k (2023) vs. net loss $(11,141)k (2024) .
Company Pay vs. Performance Snapshot
| Year | Valuation of Initial Fixed $100 Investment Based on TSR ($) | Net Income (Loss) ($000s) |
|---|---|---|
| 2023 | 30 | 5,269 |
| 2024 | 44 | (11,141) |
Investment Implications
- Alignment: Curhan’s equity stake is modest (<1%) and consists of options; alignment comes primarily from long‑dated options with explicit acceleration on change‑in‑control or sizable equity financing, potentially incentivizing strategic transactions or capital raises .
- Pay-for-Performance: Compensation structure is hourly consulting plus equity; no quantified bonus metrics were adopted, and 2024 bonus was not paid—reducing pay‑for‑performance linkage in cash but maintaining long‑term orientation via 4‑year option vesting and clawback coverage for financial restatements .
- Retention & Risk: Lack of severance for the CFO consultant reduces termination costs but may elevate turnover risk versus a traditional employment agreement; acceleration features mitigate risk of forfeiture in strategic outcomes .
- Trading Signals: No Form 4 activity located in the available dataset for Curhan; outstanding options suggest potential future exercise‑related selling pressure as tranches vest, especially if stock trades meaningfully above $6.66 strike .
- Governance: Clawback policy adds discipline; absence of pledging and related‑party transactions is favorable. Overall, the consultant model implies flexibility for Serina but a weaker cash incentive alignment versus defined financial KPIs .